Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator Drugs are a widely used medication in Switzerland, and the market for these drugs has been growing steadily in recent years.
Customer preferences: Switzerland has a high prevalence of respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), which has led to a high demand for bronchodilator drugs. Patients in Switzerland prefer to use inhalers over other forms of medication, as it provides quick relief and is easy to use.
Trends in the market: The market for bronchodilator drugs in Switzerland has been growing due to the increasing prevalence of respiratory diseases and the aging population. The demand for combination drugs, which combine bronchodilators and corticosteroids, has also been increasing in recent years. Additionally, there has been a shift towards using more environmentally friendly inhalers, which has led to the development of new inhaler technologies.
Local special circumstances: Switzerland has a highly developed healthcare system, which provides easy access to medication for patients. The country also has strict regulations for the approval of drugs, which ensures the safety and efficacy of medication. The high cost of healthcare in Switzerland has led to a focus on cost-effectiveness and the use of generic drugs, which has affected the pricing of bronchodilator drugs.
Underlying macroeconomic factors: Switzerland has a stable economy and a high standard of living, which has led to a high demand for healthcare services. The aging population and the increasing prevalence of respiratory diseases have also contributed to the growth of the bronchodilator drugs market. The country has a strong pharmaceutical industry, which has led to the development of new drugs and technologies in the market. However, the high cost of healthcare and the focus on cost-effectiveness may affect the pricing and availability of medication in the future.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
